Pfizer Inc
NYSE: PFE
$24.80
-$1.22 (-4.7%)
Closing Price on November 15, 2024
PFE Articles
October 13, 2016: Markets opened lower Thursday following a weaker view on China’s trade balance joined with worries about the Fed and third-quarter earnings leave investors with the jitters. Citi,...
Published:
Last Updated:
The September 30 short interest data have been compared with the previous figures, and for the selected pharmaceutical stocks, short interest was mixed.
Published:
Last Updated:
October 6, 2016: Markets opened slightly lower Thursday and tracked close to the break-even line for much of the day. Tomorrow’s report on non-farm payrolls for September is the week’s big data...
Published:
Last Updated:
September 29, 2016: Markets opened slightly higher again Thursday following Wednesday’s announced agreement among OPEC members to rein in production. Comments various Fed officials talking a rate...
Published:
Last Updated:
The September 15 short interest data have been compared with the previous figures, and for most of the selected pharmaceutical stocks, short interest has increased.
Published:
Last Updated:
September 26, 2016: Markets opened lower again Monday and only the recently added real-estate sector traded higher on the day. Crude oil prices were up on hopes for an agreement this week on freezing...
Published:
Last Updated:
Pfizer shares traded down marginally Monday morning after the company announced that it will abandon its plan to split into two companies.
Published:
Last Updated:
While the polls have the race pretty tight, one thing is for sure: a victory by Donald Trump would favor a far different group of stocks than a victory by Hillary Clinton.
Published:
Last Updated:
The volatility in the markets have shaken some of the top dividend leaders and may be giving long-term investors a great buying opportunity.
Published:
Last Updated:
Despite recent market headwinds and volatility, there are strong underlying fundamentals among the large cap pharmaceuticals that are continuing to drive them forward.
Published:
Last Updated:
The August 31 short interest data have been compared with the previous figures, and for most of the selected pharmaceutical stocks, short interest has significantly decreased.
Published:
Last Updated:
In a new research report, Baird notes two biotech companies in its research coverage universe that may be considered speculative takeover targets, and a third is a possible target as well.
Published:
Last Updated:
The August 15 short interest data have been compared with the previous figures, and for most of the selected pharmaceutical stocks, short interest has significantly decreased.
Published:
Last Updated:
In one of the longest running bidding wars in recent times, Pfizer has finally reeled in cancer-drug maker Medivation.
Published:
Last Updated:
Medivation has been among the top future biotech mergers for quite some time. The problem is that we still have no idea which company will buy Medivation, nor do we know what price.
Published:
Last Updated: